key: cord-0285276-34u4jeyv
authors: Portnoy, A.; Abbas, K.; Sweet, S.; Kim, J.; Jit, M.
title: Projections of human papillomavirus (HPV) vaccination impact in Ethiopia, India, Nigeria, and Pakistan: a comparative modelling study
date: 2021-06-03
journal: nan
DOI: 10.1101/2021.06.01.21258170
sha: fa0fe54d6a23bddc57de9e6859c4d26e5df2260e
doc_id: 285276
cord_uid: 34u4jeyv

Background: Cervical cancer is the second most common cancer among women in Ethiopia, India, Nigeria, and Pakistan. However, of these four countries, only Ethiopia has introduced human papillomavirus (HPV) vaccination at the national level in 2018 and India in a few states in 2016. Our study objective was to estimate the potential health impact of HPV vaccination among ten cohorts of 9-year-old girls from 2021-2030 in Ethiopia, India, Nigeria, and Pakistan using two independent mathematical models, and assess similarities and differences in vaccine impact projections through comparative modelling analysis. Methods: Using two widely published models (Harvard and PRIME) to estimate HPV vaccination impact, we simulated a vaccination scenario of 90% annual coverage among 9-year-old girls from 2021-2030 in Ethiopia, India, Nigeria, and Pakistan. We estimated the potential health impact in terms of cervical cancer cases, deaths, and disability-adjusted life years (DALYs) averted among vaccinated cohorts from the time of vaccination until 2100. We also conducted a comparative modelling analysis to understand the differences in vaccine impact estimates generated by the two models. Results: Prior to harmonising model assumptions, the range between the PRIME model and the Harvard model for the potential health impact of HPV vaccination in terms of the number of cervical cancer cases averted among girls vaccinated 2021-2030 between the year of vaccination and 2100 was: 262,000 to 270,000 in Ethiopia; 1,640,000 to 1,970,000 in India; 330,000 to 336,000 in Nigeria; and 111,000 to 133,000 in Pakistan. When harmonising model assumptions, alignment on HPV type distribution significantly narrowed the differences in vaccine impact estimates. Conclusions: The main difference in estimates for cases, deaths, and DALYs averted by vaccination between the models are due to variation in interpretation around data on cervical cancer attribution to HPV-16/18; differences in estimates for DALYs averted are additionally due to differences in age-specific remaining life expectancy over time between the two models. As countries make progress towards the World Health Organization targets for cervical cancer elimination, continued explorations of underlying differences in model inputs, assumptions, and results when examining cervical cancer prevention policy will be critical.

1 Background 1

Most new vaccine introductions in those countries have been supported through partnerships with 23 the global community, particularly Gavi, the Vaccine Alliance, and the Bill and Melinda Gates 24 Foundation (BMGF). Mathematical models of the impact of HPV vaccines have been used to 25 support programme monitoring and priority-setting by Gavi, the Vaccine Alliance, and BMGF 26 since 2011 [14] . The Vaccine Impact Modelling Consortium (VIMC) was formed in late 2016, 27 with the support of Gavi and BMGF, to bring together two groups involved in HPV modelling, 28 with others conducting impact modelling of 11 other vaccines [15] . Additionally, by ensuring that 29 at least two groups model each analysed pathogen within VIMC, the vaccine impact estimates 30 from VIMC provide an important opportunity to examine the parametric, structural, model, and 31 methodological uncertainty both within and between models [16] . Comparative modelling aims to 32 enhance model transparency and can help guide public health research and priorities. have been used extensively to inform decisions by Gavi [17, 18] , BMGF [19] , WHO [20] [21] [22] , and 39 individual countries [23, 24] . Given that both models are being used to understand HPV vaccine 40 impact in the same settings, it is important to quantitatively compare the projections made by both 41 models and to understand their differences, so that model results can be interpreted in the context 42 of each other. 43 44 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 3, 2021. ; https://doi.org/10.1101/2021.06.01.21258170 doi: medRxiv preprint

Our study objective was to estimate the potential health impact of HPV vaccination among ten 45 cohorts of 9-year-old girls from 2021-2030 in Ethiopia, India, Nigeria, and Pakistan using two 46 independent mathematical models, and assess similarities and differences in vaccine impact 47 projections through a comparative modelling analysis. We used a vaccination scenario of 90% 48 annual coverage among 9-year-old girls, in alignment with the goals of the cervical cancer 49 elimination strategy set forth by the WHO [5] [6] [7] . We estimated the potential health impact in terms 50 of cervical cancer cases, deaths, and disability-adjusted life years (DALYs) averted among 51 vaccinated cohorts from the time of vaccination until 2100 in Ethiopia, India, Nigeria, and 52

Pakistan. We also conducted a comparative modelling analysis to infer the differences in the 53 vaccine impact estimates generated by the PRIME and Harvard models. 54 55 Methods 56

We used the PRIME and Harvard models to project the impact of HPV vaccination in four high-58 burden countries (Ethiopia, India, Nigeria, and Pakistan). Both the PRIME [22, 25] and Harvard 59 [17, 23] The models assume that girls are fully immunized with a two-dose schedule with perfect timeliness 71 at the target ages and that girls effectively immunized against vaccine-targeted HPV types can 72 develop cervical cancer associated with non-vaccine HPV types; also, no cross-protection against 73 non-vaccine types nor indirect effects are assumed. The model captures burden from all HPV 74 genotypes, but the impact of vaccination is limited to the burden caused by genotypes targeted by 75 the vaccine. In this analysis, the models simulated health benefits from vaccination against HPV 76 types 16 and 18. Vaccine efficacy against HPV-16/18 infections is assumed to be 100% [26] [27] [28] [29] [30] Table 1 outlines the data sources used by the Harvard and PRIME models. Age-specific cervical 84 cancer incidence is estimated from the Globocan 2020 database of IARC [11] . For the proportion 85 of cancer that is attributed to the vaccine-covered types (e.g., HPV-16/18), PRIME uses a study 86 by Serrano et al. [31] whose data sources include a meta-analysis performed by the IARC [32] and 87 a retrospective cross-sectional worldwide study [33] , while Harvard uses the meta-analysis by the 88 IARC [32] exclusively. 89 90 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 3, 2021. To estimate cancer mortality, the Harvard model assumes country-specific distributions of cancer 91 stages [21] . The model then incorporates 5-year stage-specific survival probabilities for untreated 92 and treated cervical cancers (by region) and treatment access proportions (by country). These 93 values are combined into weighted averages to provide country-specific 5-year survival parameters 94 by stage, validated against age-specific mortality rates [11, 21] . The PRIME model uses estimates 95 of age-specific cervical cancer mortality from Globocan 2020 [11] . 107 PRIME is a multiple cohort model. It calculates population size by estimating the size of the female 108 age cohort at the age of vaccination (e.g., 9 years old) from United Nations Population Division 109 estimates [36] . The size of the age cohort in subsequent years is then calculated by constructing 110 life tables, using the time-varying probability of dying by age and country from the United Nations 111 Population Division estimates [36] . 112 113 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. using both PRIME and Harvard models. Model outcomes were aggregated over multiple birth 135 cohorts to capture the health benefits of vaccinating girls aged 9 years between 2021 and 2030 136 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 3, 2021. Figure 1A shows the differences between the data used for the proportion of cervical cancer that 145 is attributed to HPV-16/18 by the two models for Ethiopia, India, Nigeria, and Pakistan. Figure 1B  146 compares the cohort size for a cohort born in 2012 (which relates to the vaccinated cohort of 9-147

year-old girls in 2021) in the two models using Pakistan as an example; all four countries showed 148 similar differences and trends. While, on average, the differences in cohort size range from 2% to 149 6%, the differences remain small until older ages (80 years and above), when the differences 150 increased due to the decreasing population size with increasing all-cause mortality. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 3, 2021. ; https://doi.org/10.1101/2021.06.01.21258170 doi: medRxiv preprint and 6 vs. 5 in Pakistan. When harmonising the assumptions around population demography across 183 the Harvard and PRIME models, the difference in the estimated number of cervical cancer cases 184 given routine vaccination narrowed, but the difference in the estimated vaccination impact was 185 slightly increased ( Figure 3A) . However, overall, the effect of harmonising the assumptions around 186 population demography between Harvard and PRIME was small based on this metric, resulting in 187 an equivalent estimate of the number of cervical cancer cases averted per 1,000 fully vaccinated 188 girls as the base case Harvard and PRIME models. On the other hand, when harmonising the 189 assumptions around HPV-16/18 type distribution between the Harvard and PRIME models ( Figure  190 3B), the differences in estimated vaccination impact were nearly eliminated. Thereby, we infer 191 that the main difference in estimates for cases averted by vaccination between the two models is 192 due to variations in cervical cancer attribution to HPV-16/18. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 3, 2021. ; https://doi.org/10.1101/2021.06.01.21258170 doi: medRxiv preprint women [32] , whereas the PRIME model relied on an estimation of invasive cervical cancer based 206 on this same meta-analysis [32] that accounts for multi-type infections through proportional 207 weighting attribution [31] . 208 209 HPV-16/18 vaccination was estimated to avert substantial numbers of cervical cancer cases, 210 deaths, and DALYs by both the Harvard model and the PRIME model. However, routine HPV 211

vaccination has yet to be introduced in any of these four high-burden countries at the national level 212 (although a nationwide single-age cohort campaign of 14-year-old girls was conducted in Ethiopia 213 in 2018-2019 [12] and India introduced in a few states in 2016 [13] ). In order to accelerate progress 214 towards cervical cancer elimination, preventing cervical cancer through HPV vaccination will be 215 an essential strategy in these countries, particularly given the low coverage and access to cervical 216 cancer screening [8] . Understanding similarities and differences between HPV vaccination impact 217 predicted by different models will be crucial, given that key questions about which countries to 218 prioritise and which vaccination strategies to use will be important in an era of HPV vaccine dose 219 shortages [38] and COVID-19-related disruptions to vaccination programmes [39, 40] . 220

The size of the relevant population at each year of age is critical because it determines the number 222 of people who are exposed to the risk of cervical cancer and can therefore be protected by 223 vaccination. Both methods used to estimate the at-risk population have strengths and limitations. 224

In the PRIME model, the size of the age cohort in subsequent years is calculated by constructing 225 life tables, using the time-varying probability of dying by age and country from the United Nations 226 Population Division estimates [36] . The Harvard method captures such changes, but also includes 227 future population change due to migration, which may not reflect the same vaccination status as 228 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 3, 2021.

the locally-born population. In general, as the demography differences are minimal between the 229 two models, the vaccination impact estimates are similar for each country when demography is 230 switched to align with the alternative model. The main driver of the differences in the vaccination 231 impact was HPV-16/18 type distribution-or, the proportion of cervical cancers that can be averted 232 by the bivalent vaccine, which has a direct relationship with vaccination impact. 233 234 This comparative modelling exercise highlighted differences in the estimates of health impact of 235 HPV vaccination due to model uncertainty. We note that HPV vaccine projections are particularly 236 susceptible to large swings in estimated health outcomes due to even small changes in fertility and 237 mortality because of the long time horizons needed in the models. Comparative modelling 238 exercises as we have done can enhance model transparency and clarify the range of uncertainty in 239 vaccine impact. Hence, the differences between the models are a strength that reflects the variation 240 and uncertainty in the projected health outcomes of vaccination impact. Understanding the inter-241 model variation improves the quality and coordination of vaccine impact assessment, which in 242 turn can help guide public health research and priorities in cervical cancer elimination and control. 243 244 Similar comparative modelling exercises were conducted to examine the timeline to cervical 245 cancer elimination in LMICs [20, 21] . Relying on evidence synthesis from different models was 246 deemed an essential aspect to inform strategies for cervical cancer elimination by the WHO [5, 247 41] . However, these analyses relied on estimations of age-standardized cervical cancer incidence, 248 such that demographic changes were not expected to drive the uncertainty in the timing of 249 elimination. 250 251 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 3, 2021. ; https://doi.org/10.1101/2021.06.01.21258170 doi: medRxiv preprint There are several important limitations to this analysis. As we relied on static cohort models in 252 these analyses, we were only able to estimate direct effects for vaccinated women, which excluded 253 additional indirect benefits from herd immunity for unvaccinated women. We projected 254 intervention impact for only ten cohorts of 9-year-old girls in four countries and assumed that 255 cervical cancer incidence rates affecting these cohorts would be stable over the time period of the 256 analysis. Vaccine efficacy against high-risk HPV types other than HPV-16/18 (i.e., cross-257 protection) was not included. We did not examine cervical cancer screening programs in this 258 analysis and assumed that any ongoing screening programs did not change as HPV Both models project that HPV vaccination will have a large impact on morbidity and mortality in 266 the four countries we examined. The differences in outcomes between the models capture variation 267 in interpretation around data on cervical cancer epidemiology and future demographic change. 268

This study highlights that HPV type distribution is a critical input to modelling the potential health 269 impact of vaccination. The main difference in estimates for cases and deaths averted by vaccination 270 between the models capture variation in interpretation around data on cervical cancer attribution 271 to HPV-16/18. The main differences in estimates for DALYs averted by vaccination between the 272 models are due to variations in cervical cancer attribution to HPV-16/18 and age-specific 273 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 3, 2021. 

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

The authors declare that they have no competing interests.

This work was carried out as part of the Vaccine Impact Modelling Consortium (www.vaccineimpact.org), but the views expressed are those of the authors and not necessarily those of the Consortium or its funders. The funders were given the opportunity to review this paper prior to publication, but the final decision on the content of the publication was taken by the authors. Authors' contributions AP, KA, and MJ conceptualized and designed the study. AP and KA did the analysis, drafted the initial manuscript, and approved the final manuscript as submitted. SS, JJK, and MJ critically reviewed the analysis, reviewed and revised the manuscript, and approved the final manuscript as submitted. Tables  Table 1 . Data sources for Harvard and PRIME models.

Harvard PRIME . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 3, 2021. 

Harvard PRIME Harvard with PRIME type distribution PRIME with Harvard type distribution

Global burden of human papillomavirus and related diseases

Epidemiologic classification of human papillomavirus types associated with cervical cancer

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial

Global elimination of cervical cancer as a public health problem. The Lancet Oncology

World Health Organization: Accelerating cervical cancer elimination

World Health Organization: Cervical cancer elimination strategy

HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019

Cervical cancer prevention and the Millennium Development Goals

International Agency for Research on Cancer: GLOBOCAN 2020. Cancer incidence, mortality and prevalence worldwide

Accessed 26

Verguet S: Health gains and financial protection from human papillomavirus vaccination in Ethiopia: findings from a modelling study

Current status of human papillomavirus vaccination in India's cervical cancer prevention efforts

The estimated mortality impact of vaccinations forecast to be administered during 2011-2020 in 73 countries supported by the GAVI Alliance

Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study

Modelling the epidemiology of infectious diseases for decision analysis: a primer

Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries

Potential lives saved in 73 countries by adopting multi-cohort vaccination of 9-14-year-old girls against human papillomavirus

Choosing the optimal HPV vaccine: The health impact and economic value of the nonavalent and bivalent HPV vaccines in 48 Gavi-eligible countries

Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries

Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lowermiddle-income countries

Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study

Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country

Cervical cancer treatment costs and cost-effectiveness analysis of human papillomavirus vaccination in Vietnam: a PRIME modeling study

Effects of updated demography, disability weights, and cervical cancer burden on estimates of human papillomavirus vaccination impact at the global, regional, and national levels: a PRIME modelling study

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

Crossprotective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis

Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

A review of clinical trials of human papillomavirus prophylactic vaccines

Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease

Human papillomavirus types in 115,789 HPV-positive women: A meta-analysis from cervical infection to cancer

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

Vaccine Impact Modelling Consortium: General Guidance for DALYs calculation

Global Burden of Disease Collaborative Network: Global Burden of Disease Study 2017 (GBD 2017) Disability Weights. In. Seattle, United States: Institute for Health Metrics and Evaluation

United Nations: World Population Prospects. United Nations Population Division

World Health Organization: Life tables for WHO member states

World Health Organization: Global market study: HPV vaccines. World Health Organization

World Health Organization: Pulse survey on continuity of essential health services during the COVID-19 pandemic

World Health Organization: Immunization and COVID-19 -Second pulse poll offers a more detailed understanding of disruptions to vaccination caused by COVID-19 and how to respond

World Health Organization: Global strategy to accelerate the elimination of cervical cancer as a public health problem

We would like to thank Caroline L. Trotter and Alicia N.M. Kraay who provided valuable comments during a review of these models organized by the Vaccine Impact Modelling Consortium.